These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 25319654)

  • 1. Use of guanidinopropyl-modified siRNAs to silence gene expression.
    Buff MC; Bernhardt S; Marimani MD; Ely A; Engels JW; Arbuthnot P
    Methods Mol Biol; 2015; 1218():217-49. PubMed ID: 25319654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of hepatitis B virus replication in cultured cells and in vivo using 2'-O-guanidinopropyl modified siRNAs.
    Marimani MD; Ely A; Buff MC; Bernhardt S; Engels JW; Arbuthnot P
    Bioorg Med Chem; 2013 Oct; 21(20):6145-55. PubMed ID: 23743442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of 2'-O-guanidinopropyl-modified nucleoside phosphoramidites and their incorporation into siRNAs targeting hepatitis B virus.
    Brzezinska J; D'Onofrio J; Buff MC; Hean J; Ely A; Marimani M; Arbuthnot P; Engels JW
    Bioorg Med Chem; 2012 Feb; 20(4):1594-606. PubMed ID: 22264759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of replication of hepatitis B virus in transgenic mice following administration of hepatotropic lipoplexes containing guanidinopropyl-modified siRNAs.
    Marimani MD; Ely A; Buff MC; Bernhardt S; Engels JW; Scherman D; Escriou V; Arbuthnot P
    J Control Release; 2015 Jul; 209():198-206. PubMed ID: 25937322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological properties of chemically modified siRNAs bearing 1-deoxy-D-ribofuranose in their 3'-overhang region.
    Taniho K; Nakashima R; Kandeel M; Kitamura Y; Kitade Y
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2518-21. PubMed ID: 22377516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solid-phase synthesis of siRNA oligonucleotides.
    Beaucage SL
    Curr Opin Drug Discov Devel; 2008 Mar; 11(2):203-16. PubMed ID: 18283608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of nuclease-resistant siRNAs possessing universal overhangs.
    Ueno Y; Watanabe Y; Shibata A; Yoshikawa K; Takano T; Kohara M; Kitade Y
    Bioorg Med Chem; 2009 Mar; 17(5):1974-81. PubMed ID: 19200743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Building siRNAs with Cubes: Synthesis and Evaluation of Cubane-Modified siRNAs.
    Hammill ML; Salim L; Tsubaki K; Varley AJ; Kitamura M; Okauchi T; Desaulniers JP
    Chembiochem; 2021 Oct; 22(20):2981-2985. PubMed ID: 34319643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expressing functional siRNAs in mammalian cells using convergent transcription.
    Tran N; Cairns MJ; Dawes IW; Arndt GM
    BMC Biotechnol; 2003 Nov; 3():21. PubMed ID: 14604435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs.
    Aigner A
    J Biotechnol; 2006 Jun; 124(1):12-25. PubMed ID: 16413079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted gene silencing by small interfering RNA-based knock-down technology.
    Zhang J; Hua ZC
    Curr Pharm Biotechnol; 2004 Feb; 5(1):1-7. PubMed ID: 14965205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and screening of siRNAs against highly structured RNA targets.
    Nasheri N; Pezacki JP; Sagan SM
    Methods Mol Biol; 2013; 942():69-86. PubMed ID: 23027046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene-silencing properties of siRNAs that contain internal amide-bond linkages.
    Gong W; Desaulniers JP
    Bioorg Med Chem Lett; 2012 Nov; 22(22):6934-7. PubMed ID: 23062704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation of Lipid-Conjugated siRNA Oligonucleotides for Enhanced Gene Inhibition in Mammalian Cells.
    Grijalvo S; Ocampo SM; Perales JC; Eritja R
    Methods Mol Biol; 2021; 2282():119-136. PubMed ID: 33928573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and silencing properties of siRNAs possessing lipophilic groups at their 3'-termini.
    Ueno Y; Kawada K; Naito T; Shibata A; Yoshikawa K; Kim HS; Wataya Y; Kitade Y
    Bioorg Med Chem; 2008 Aug; 16(16):7698-704. PubMed ID: 18644731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transfection of siRNAs in multiple myeloma cell lines.
    Brito JL; Brown N; Morgan GJ
    Methods Mol Biol; 2010; 623():299-309. PubMed ID: 20217559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonviral in vivo delivery of therapeutic small interfering RNAs.
    Aigner A
    Curr Opin Mol Ther; 2007 Aug; 9(4):345-52. PubMed ID: 17694447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of hepatitis B virus (HBV) by LNA-mediated nuclear interference with HBV DNA transcription.
    Sun Z; Xiang W; Guo Y; Chen Z; Liu W; Lu D
    Biochem Biophys Res Commun; 2011 Jun; 409(3):430-5. PubMed ID: 21596023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of oligonucleotides with glucosamine at the 3'-position and evaluation of their biological activity.
    Luo X; Sugiura T; Nakashima R; Kitamura Y; Kitade Y
    Bioorg Med Chem Lett; 2013 Jul; 23(14):4157-61. PubMed ID: 23743279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular Delivery of siRNAs Using Bolaamphiphiles.
    Gupta K
    Methods Mol Biol; 2017; 1632():187-205. PubMed ID: 28730440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.